厄洛替尼致消化系统严重不良反应文献分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (452 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the occurrence and clinical characteristics of serious adverse drug reactions (ADRs) of the digestive system caused by Erlotinib, and to provide references for clinical rational use of drugs. Methods The literature on ADRs of the digestive system caused by Erlotinib contained in the Chinese national knowledge infrastructure (CNKI), VIP, PubMed, Medline, and Web of Science from the establishment of the database to January 2020 were searched, while they were performed statistical analysis. Results There were 25 cases of severe ADRs in the digestive system caused by Erlotinib; the age distribution was 51 to 80 years old (20 cases, 80%); most of them occur within 8 weeks after medication (19 cases, 76%); it was more common with gastrointestinal perforation (24%), drug-induced liver injury (52%), and new serious ADRs such as reflex reminiscence gastritis. Conclusion Clinicians and pharmacists need to strengthen their understanding and monitoring of severe ADRs in the digestive system caused by Erlotinib, and carefully evaluate the treatment risks of re-dose to ensure safe and effective clinical use.

Key words： Erlotinib Adverse drug reactions Digestive system Literature analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Ran FANG Yuting SU Dan LI Min SHEN Aizong

Cite this article:

ZHOU Ran FANG Yuting SU Dan LI Min SHEN Aizong. Literature analysis on severe adverse drug reactions of digestive system by Erlotinib[J]. 中国医药导报, 2021, 18(12): 150-153.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I12/150

[1] Li XY，Lin JZ，Yu SH. Front-line therapy in advanced non-small cell lung cancer with sensitive epidermal growth factor receptor mutations：A network meta-analysis [J]. Clin Ther，2020，42（2）：338-350.
[2] Cheon YH，Kim MJ，Kang MG，et al. Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer [J]. Yonsei Med J，2011，52（4）：695-698.
[3] Gass-Jégu F，Gschwend A，Gairard-Dory AC，et al. Gastrointestinal perforations in patients treated with erlotinib： A report of two cases with fatal outcome and literature review [J]. Lung Cancer，2016，99：76-78.
[4] Rafiullah，Shah WS，Majid NA，et al. Duodenal perforation secondary to erlotinib therapy in a patient with non-small cell lung cancer [J]. WMJ，2017，116（1）：34-36.
[5] Yamaguchi T，Gotoh Y，Hattori H，et al. Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations：A case report [J]. Oncol Lett，2018，16（1）：1046-1050.
[6] Bai H，Liu Q，Shi M，et al. Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding [J]. Pak J Med Sci，2013，29（5）：1278-1279.
[7] Graziani C，Hegde S，Saif MW. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer [J]. Anticancer Res，2014，34（12）：7339-7343.
[8] Choi SJ，Kim HJ，Kim JS，et al. Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI-a case report [J]. BMC Cancer，2016，16：588.
[9] Silvano G，Lazzari G，Lovecchio M，et al. Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient：a case report [J]. Lung Cancer，2008， 61（2）：270-273.
[10] 王方舟，张明月，王韧韬，等.肺移植后肺癌患者联用厄洛替尼和他克莫司致严重不良反应1例并文献复习[J].中国药物应用与监测，2017，14（4）：251-258.
[11] Liu W，Makrauer FL，Qamar AA，et al. Fulminant hepatic failure secondary to erlotinib [J]. Clin Gastroenterol Hepatol，2007，5（8）：917-920.
[12] Gunturu KS，Abu-Khalaf M，Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib：a possible etiology of complications in a patient with pancreatic cancer [J]. JOP，2010，11（5）：484-485.
[13] Pellegrinotti M，Fimognari FL，Franco A，et al. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer [J]. Ann Pharmacother，2009，43（3）：542-545.
[14] Huang YS，An SJ，Chen ZH，et al. Three cases of severe hepatic impairment caused by erlotinib [J]. Br J Clin Pharmacol，2009，68（3）：464-467.
[15] Ueda H，Hayashi H，Kudo K，T et al. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity [J]. Invest New Drugs，2016，34（6）：797-799.
[16] Ramanarayanan J，Scarpace SL. Acute drug induced hepatitis due to erlotinib [J]. JOP，2007，8（1）：39-43.
[17] Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer [J]. Clin Adv Hematol Oncol，2008， 6（3）：191-199.
[18] 张会娟，侯小萌，张力.厄洛替尼治疗NSCLC致急性胆汁淤积型药物性肝病1例[J].癌症进展，2013，11（4）：376-378.
[19] 史桂兰，王莹，于文瀚.厄洛替尼致转氨酶重度升高1例报道[J].中国实验诊断学，2013，17（9）：1731.
[20] Lai YC，Lin PC，Lai JI，et al. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid：a case report and literature review [J]. Int J Clin Pharmacol Ther，2011， 49（7）：461-466.
[21] 郑策，甄健存.厄洛替尼致肌酸激酶升高、肝酶升高、食欲减退1例[J].中国药物警戒，2013，10（6）：382.
[22] Ruinemans GM，Balemans C，Mattijssen V，et al. Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib [J]. Lung Cancer，2010，70（3）：364-365.
[23] Seto T，Kato T，Nishio M，et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations （JO25567）：an open-label，randomised，multicentre，phase 2 study [J]. Lancet Oncol，2014，15（11）：1236-1244.
[24] Levy A，Hollebecque A，Bourgier C，et al. Targeted therapy-induced radiation recall [J]. Eur J Cancer，2013，49（7）：1662-1668.
[25] 中华医学会肝病学分会药物性肝病学组[J].药物性肝损伤诊治指南[J].实用肝脏病杂志，2017，20（2）：133-150.